Results 151 to 160 of about 1,626 (189)
Journal of International Medical Research, 2013 Objective To compare the efficacy of ramosetron, midazolam, and the combination of ramosetron and midazolam in the prevention of postoperative nausea and vomiting (PONV) in female patients undergoing thyroidectomy.
Young Cheol Woo +2 more
exaly +3 more sources
Journal of Anesthesia, 2009 PURPOSE: Ramosetron can be administered orally as well as intravenously. We investigated the effect of oral ramosetron on postoperative nausea and vomiting (PONV) in patients undergoing gynecological laparoscopy.
Ji Young Kim +2 more
exaly +2 more sources
Journal of International Medical Research, 2013 Objectives This randomized, double-blind study compared the antiemetic efficacy of ramosetron with that of ramosetron combined with midazolam, and investigated whether the timing of midazolam administration affected the incidence of postoperative nausea and vomiting (PONV).
Soo Kyung Lee +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Population pharmacokinetics of ramosetron
Journal of Pharmacokinetics and Pharmacodynamics, 2015Ramosetron is a selective serotonergic 5-hydroxy-tryptamine receptor 3 antagonist that is used to prevent and treat postoperative nausea and vomiting. This study aimed to characterize the population pharmacokinetics of ramosetron in patients undergoing surgery with general anesthesia.
Seong Heon Lee +3 more
openaire +2 more sources
Supportive Care in Cancer, 2004
To establish whether the combination of a corticosteroid (dexamethasone) and the newer serotonin-3 (5-HT(3)) receptor antagonist ramosetron is superior to ramosetron alone in controlling cisplatin-induced emesis.A total of 283 patients aged 18-75 years with confirmed malignant disease who were scheduled to receive cisplatin > or =50 mg/m(2) with or ...
Antonio, Villalon, Valorie, Chan
exaly +3 more sources
To establish whether the combination of a corticosteroid (dexamethasone) and the newer serotonin-3 (5-HT(3)) receptor antagonist ramosetron is superior to ramosetron alone in controlling cisplatin-induced emesis.A total of 283 patients aged 18-75 years with confirmed malignant disease who were scheduled to receive cisplatin > or =50 mg/m(2) with or ...
Antonio, Villalon, Valorie, Chan
exaly +3 more sources
Comparison of the antiemetic effect of ramosetron and combined ramosetron and midazolam in children
European Journal of Anaesthesiology, 2012Postoperative nausea and vomiting remains a clinically important problem after strabismus surgery in children.To study the benefit of adding midazolam to ramosetron on the incidence of postoperative nausea, retching or vomiting and on the incidence of postoperative agitation.A randomised, double-blind comparison.The operating theatre suite and day care
Hyo-Jin, Byon +3 more
openaire +2 more sources
Clinical Drug Investigation, 2005
To assess the efficacy and tolerability of a combination of ramosetron and dexamethasone compared with ramosetron alone in the prevention of cisplatin-induced emesis.Prospective, randomised, single-blind, crossover study.Thirty-four chemotherapy-naive patients with stomach cancer or sar-coma scheduled to receive two consecutive courses of cisplatin ...
Jeong Hye, Kim +6 more
openaire +2 more sources
To assess the efficacy and tolerability of a combination of ramosetron and dexamethasone compared with ramosetron alone in the prevention of cisplatin-induced emesis.Prospective, randomised, single-blind, crossover study.Thirty-four chemotherapy-naive patients with stomach cancer or sar-coma scheduled to receive two consecutive courses of cisplatin ...
Jeong Hye, Kim +6 more
openaire +2 more sources
Mucoadhesive suppositories of ramosetron hydrochloride utilizing Carbopol®
International Journal of Pharmaceutics, 2000Suppositories are the preferable dosage form for patients at home or experiencing nausea. Serotonin (5-HT(3))-receptor antagonists are used to treat vomiting in intravenous or oral administration but not suppository form. Ramosetron hydrochloride (RAM) is a new 5-HT(3) antagonist which effectively inhibits vomiting, and we prepared RAM suppositories ...
R Yahagi, Y Machida, H Onishi, Y Machida
openaire +2 more sources
Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for IBS
Inflammopharmacology, 2007Ramosetron is a potent and selective serotonin (5-HT)(3) receptor antagonist that has been shown to affect abnormal colonic function and abdominal pain in animals. Ramosetron (0.3 to 100 microg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing ...
T, Hirata +4 more
exaly +3 more sources
European Journal of Clinical Pharmacology, 2008
The aim of our study was to investigate the effects of multiple doses of paroxetine on the pharmacokinetics, safety, and tolerability of a single oral 10-microg dose of ramosetron. METHODS This was an open, one-sequence crossover design study. On day 1, healthy male and female subjects were administered a single dose of 10 microg ramosetron.
Akito Nishida
exaly +3 more sources
The aim of our study was to investigate the effects of multiple doses of paroxetine on the pharmacokinetics, safety, and tolerability of a single oral 10-microg dose of ramosetron. METHODS This was an open, one-sequence crossover design study. On day 1, healthy male and female subjects were administered a single dose of 10 microg ramosetron.
Akito Nishida
exaly +3 more sources